Daily Cannabis News Brief for 9/3/2026

President Trump signed H.R. 6500, temporarily delaying most new federal hemp restrictions from November 12 until December 11. The provisions include a new total THC standard and a 0.4-milligram-per-container limit for final hemp-derived cannabinoid products. Restrictions on cannabinoids that cannot occur naturally in cannabis will still take effect November 12.

The Alaska Marijuana Control Board is considering a proposal that would eliminate the state’s seven-gram daily purchase limit for inhalable marijuana concentrates and its 5,600-milligram combined THC limit. The existing one-ounce limit for usable marijuana would remain. The proposal is part of a broader state effort to reduce regulatory requirements and remains under development.

Mississippi licensed dispensaries recorded $158.8 million in medical marijuana sales during fiscal year 2026, according to state data. Sales reached their highest quarterly level during the final three months of the fiscal year, at $42.2 million. The state also collected more than $8.36 million from its medical marijuana excise tax and dispensary license fees.

Great Britain is moving toward its first CBD novel food authorizations after the Food Standards Agency recommended approval of three high-purity CBD applications linked to approximately 3,000 products already on the market. The agency’s board will consider the recommendations September 16 before submitting advice to ministers in England and Wales, who will make the final decisions.

A study analyzing more than 16,000 survey responses from New York medical marijuana patients found that 49% said they could not afford enough cannabis to adequately manage their symptoms. Among veterans, the figure reached 55%. Only 26% of respondents agreed that medical marijuana prices were reasonable, with cost increasingly cited as a reason patients may leave the program.

Researchers from the University of São Paulo found that cannabigerol (CBG) produced antipsychotic-like effects across several behavioral tests in mouse models of schizophrenia. CBG reduced disruptions involving sensorimotor gating, hyperactivity, social interaction and recognition memory. Researchers said the findings support further investigation of the non-intoxicating cannabinoid as a potential candidate for psychiatric research.

A survey of 5,383 people with eating disorders found marijuana use was common, with 56.1% reporting use during the past year. Participants with anorexia nervosa and avoidant/restrictive food intake disorder were particularly likely to report benefits involving food-related anxiety, nausea and difficulty eating. Researchers cautioned that the self-reported findings do not establish marijuana as an effective treatment.

CBD altered gene regulation in human prostate cancer cell lines and enhanced the effects of several existing cancer treatments in a new preclinical study. Researchers observed particularly strong effects when CBD was combined with the hormonal treatment enzalutamide, while combinations with other targeted treatments also reduced cancer cell viability. The findings were limited to cultured cells and require further research.

Connecticut regulators issued new guidance allowing registered employees at medical marijuana dispensaries and hybrid retailers to prepare and complete patient sales without a pharmacist physically onsite. A licensed pharmacist must remain available for remote consultation within two hours and in-person consultation within two business days, while registered employees handling sales must complete four hours of required marijuana-related education.

New York’s licensed adult-use marijuana cultivation canopy increased 32% from March to August, rising from 9.1 million to 12 million square feet. The Office of Cannabis Management said 67 cultivation tier increases have been approved since March, adding an estimated 127,000 pounds of annual production capacity, while 27 new licenses authorized to cultivate have also been issued.

New guidance from Maine’s Office of Cannabis Policy says registered medical marijuana caregivers can conduct certain sales at trade shows, industry events and some public spaces without obtaining a state event permit.

THC enhanced oxycodone’s pain-blocking effects and delayed the development of tolerance in mice, according to research from Washington University in St. Louis. The combination produced stronger and longer-lasting effects than either drug alone during the early days of treatment, including after tolerance emerged to the individual treatments. By day five, however, tolerance had developed across all groups.

The New York Cannabis Control Board approved 19 new adult-use marijuana licenses, bringing the statewide total issued to 2,342. The approvals included cultivators, distributors, microbusinesses, processors and retailers. Six new adult-use retail dispensary licenses and one Conditional Adult-Use Retail Dispensary license were among the approvals, some of which moved forward despite objections from local governments or community boards.

The Alaska Marijuana Control Board rejected a marijuana handler training course after Chair Bailey Stuart raised concerns that portions appeared AI-generated and contained numerous factual errors. Problems included references to nonexistent regulations and incorrect guidance suggesting IDs need not be checked for customers who appear older than 35. The company may submit a new course before the board’s November meeting.

Cannabis plants exposed to prolonged temperatures of 113°F experienced reduced THC and CBD production, according to a study published in Plant Stress. Cannabinoid levels began declining after 80 hours, alongside reduced activity in genes responsible for cannabinoid biosynthesis. Researchers also documented substantial oxidative stress and said extreme heat could threaten cannabis productivity as global temperatures rise.

Montana’s Department of Revenue is proposing extensive new disclosure requirements for marijuana businesses using outside financing, management, consulting, staffing or other services. Licensees would have to provide contracts, organizational information and details about compensation and operational authority before third parties begin work. Written comments on the proposal are being accepted through September 8.

Higher doses of CBD and THC significantly reduced cold hypersensitivity in mice with Parkinsonian features, according to a study published in The Journal of Neurobehavioral Sciences. Researchers also observed favorable changes in several oxidative stress markers. The authors said the findings do not establish cannabinoids as a treatment for Parkinson’s disease-associated pain and require further study.

A survey of 1,502 registered U.S. voters found substantially more support for parental notification, community service and drug education than jail when responding to attempted underage marijuana purchases. Seventy-nine percent supported notifying parents, 64% favored community service and 58% backed drug education, while just 18% supported jail time.

Cannabigerol (CBG) and a predominantly CBD full-spectrum cannabis extract both reduced inflammatory pain in animal models. In an acute experiment, CBG reduced pain-related behaviors by as much as 87.1%, while the full-spectrum extract produced reductions reaching 99.2%. During longer-term testing, repeated treatment with the highest doses of both compounds significantly improved sensitivity to mechanical pain.